Swedish company Mölnlycke Health Care, an international leader in the field of treating wounds, led the private placement. Israeli biopharmaceutical company MediWound (Nasdaq: MDWD), which has developed products for treatment of burns and wounds, has announced that it has raised $25 million in a private placement led by Swedish company Mölnlycke Health Care, an international leader in the field of treating wounds. Over the past few weeks, MediWound's share price has risen 40% on rumors of the company's sale to US firm Solventum (NYSE: SOLV), and at the end of trading yesterday MediWound had a market cap of $196 million.
The share price of Clal Biotechnology (TASE: CBI) is down 13% today and MediWound's share price opened today down 3% on Wall Street. RELATED ARTICLES MediWound jumps on reports of $400m bid by Solventum FDA approves MediWound burns treatment Israeli investment house Yelin Lapidot also participated in the private placement at a price of $17.20 per share, a 19% discount on the share price this morning before the announcement of the fund raising.
All options open The private placement now suggests that an acquisition of MediWound is not expected anytime soon, but it does not rule out the possibility of such a deal in the future. As part of the capital raising, Mölnlycke does not receive marketing rights for MediWound's products, so everything is open as far as the Israeli biopharmaceutical company is concerned. However, the agreement signed between the comp.
